Skip to main content

Home/ health information/ Group items tagged Pharmacy-payment-Scheme

Rss Feed Group items tagged

pharmacybiz

Delay in new hub and spoke legislation far from ideal - 0 views

  •  
    Community pharmacy is stuck in a vicious circle. Pharmacies are closing at an alarming rate whilst the government is talking about moving care away from hospitals and into the community to focus on preventative care. While the government talks about this vision for the future, the stark reality is that pharmacies are already struggling to meet the current Pharmacy First thresholds. And now we discover that one of the key components that could create capacity in pharmacy to deliver more clinical services has been put on hold…indefinitely. The recently published Darzi review, which was commissioned after the new government came to power to assess the state of the NHS, praised the value of community pharmacies and preventative services. But it recognised the level of pharmacy closures across the country and warned pharmacy access could be 'at risk'. Community pharmacy is ideally placed to deliver the government's vision of preventative care in the community. But let's all be clear, moving preventative services into community pharmacies has, so far, been nowhere near as successful as it could have been due to the current climate pharmacies find themselves in. The Pharmacy First scheme is a testament to this. Just this week it was announced that consultation thresholds for the Pharmacy First scheme have been reduced from 30 consultations to 20. It's the second time in three months that the thresholds have been reduced and it follows an intervention from Community Pharmacy England who wanted to "save many pharmacies from missing out on a vital payment this month." In June alone, 3,269 participating pharmacies failed to meet the threshold - that's almost a third of all community pharmacies in England.
pharmacybiz

Pharmacy Quality Scheme 2022/23 begins from 10th October'22 - 0 views

  •  
    The Pharmaceutical Services Negotiating Committee (PSNC) has reminded community pharmacy contractors to start working on the quality criteria if they intend to meet the Respiratory domain of the Pharmacy Quality Scheme (PQS) 2022/23. For respiratory domain, community pharmacy contractors  must start working towards inhaler waste management; use of a spacer in patients aged 5-15 years; and personalised asthma action plans, from today (10 October). Resources are also available to support contractors with meeting the above criteria on the PQS hub page. PSNC also informed that contractors are also now able to make a claim for an Aspiration payment for the PQS 2022/23 on the NHS Business Services Authority (NHSBSA)  Manage Your Service (MYS) portal. "The Aspiration payment is optional; if contractors do not want to claim it, it will not impact on the contractor's ability to claim a PQS payment during the declaration period. There is also no requirement to have claimed for a previous PQS to claim an Aspiration payment for PQS 2022/23.
pharmacybiz

PQS Deadline Extended Ease Pressure On Community Pharmacies - 0 views

  •  
    To ease pressure on community pharmacies, the deadline to meet the requirements of the Pharmacy Quality Scheme will be extended, Pharmaceutical Services Negotiating Committee (PSNC) announced today (December 15). This follows an agreement reached between the negotiator and the NHS England and NHS Improvement (NHSE&I) and the Department of Health and Social Care (DHSC). Recognising the challenges faced by pharmacies and their contribution towards the Covid-19 vaccination programme, following additional changes have been agreed upon: Contractors will not be required to complete the Community Pharmacy Patient Questionnaire for 2021/2022; The requirement for pharmacy teams to complete a national audit (intended to be on valproate) in 2021/22 will be waived; and The requirement for pharmacy teams to complete a contractor-chosen clinical audit in 2021/22 will be waived.
pharmacybiz

https://www.pharmacy.biz/new-pharmacy-quality-scheme-begins-next-month/ - 0 views

  •  
    The Pharmaceutical Services Negotiating Committee (PSNC) has announced that the new Pharmacy Quality Scheme (PQS) for this year will officially begin on October 10. From previous scheme £75m funding is also available and contractors will be able to claim an 'Aspiration payment' if they wish to, later this year. PSNC, the Department of Health and Social Care and NHS England have agreed the arrangements for the 2022/23 PQS, as well as those for the 2023/24 PQS, with a focus on supporting recovery from Covid-19 and wider national health priorities. The committee said: "In our negotiations on the scheme, PSNC has managed to reduce the scope of this year's PQS so that the estimated contractor costs and time required to complete the criteria will be below those associated with the original NHS proposals for the scheme." "A further reduction in scope has also been agreed due to the delayed start of the 2022/23 PQS. PSNC hopes that this, along with arguing for more realistic targets across the scheme, will help reduce the impact on contractor workload, at what continues to be a very busy and pressured period for the sector."
pharmacybiz

PhAS 2022: 1,445 pharmacies are now eligible - 0 views

  •  
    The Department of Health and Social Care has updated the list of community pharmacies eligible for the Pharmacy Access Scheme (PhAS) and approved 43 cases out of 63 applications, bringing the the total number of eligible pharmacies in England to 1,445. Earlier this year, NHS England and NHS Improvement (NHSE&I) invited community pharmacy contractors to apply for a review if they believed there were any inaccuracies in relation to pharmacy premises addresses or unforeseen circumstances affecting access, such as a permanent roadblock. Submitted applications were reviewed by the relevant NHSE&I regional pharmacy contract team, and determined by the relevant pharmaceutical services regulations committees (PSRC). Due to the workload pressures seen over winter, the review deadline was extended, giving contractors applying for a review two full months to complete their applications. This also pushed back the announcement of the outcome of the review, but where an application has been successful, PhAS payments will be backdated to the start of the scheme.
pharmacybiz

9k Pharmacy Contractors Benefit Earlier Advance Payment - 0 views

  •  
    More than 9,300 pharmacy contractors would benefit from earlier advance payment in February, Pharmaceutical Services Negotiating Committee (PSNC) said in an update. Contractors who declared their January 2022 FP34C submission figures through the Manage Your Service (MYS) portal by February 5 will receive earlier advance payments by today (February 10). The statistics indicates nearly 2,000 contractors will not receive any earlier advance payment this month, either because their January declarations were submitted late or they used the paper FP34C submission document to make their declaration, PSNC said. These contractors will receive their advance payments in accordance with the normal payment timetable i.e. on March 1. The negotiator reminded contractors that from April 2022 MYS will be the only process to make monthly submissions.
pharmacybiz

CPE Aims for Expanded Services Agreement with DHSC and NHSE - 0 views

  •  
    Community Pharmacy England (CPE) is aiming to reach an agreement with the Department of Health and Social Care (DHSC) and NHS England (NHSE) on negotiation with regards to expanded services and payment model in the pharmacy sector. Chief Executive Janet Morrison, said: "We are working at pace in negotiations with DHSC and NHSE. The process remains on track with the Government's original timescale - i.e. aiming for agreement in July, with cross-government clearance later in July, and implementation from July through to September." CPE is involved in working groups on service expansion of Hypertension Case-Finding and the Pharmacy Contraception Scheme and service design for the Common Conditions Service; and are in in-depth negotiations on Payment models. These discussions critically look at the balance between funding core capacity and activity payments, how the funding streams will be distributed and how CPE will measure delivery and impact. NHSE has been leading on the development of the PGD pathways for each of the 7 conditions, with external medical, pharmacy and other experts feeding into the process - pharmacy owners from the Community Pharmacy England Committee have also been involved but the discussions are clinically led to ensure they comply with NICE principles and concur with Antimicrobial Stewardship policy.
pharmacybiz

Aspiration payment Remainder PSNC: 2 weeks left to claim - 0 views

  •  
    The Pharmaceutical Services Negotiating Committee (PSNC) has reminded community pharmacy contractors that they have two weeks left to claim an Aspiration payment for the Pharmacy Quality Scheme (PQS) 2022/23. The window for claiming the payment will close at 11.59pm on 4 November 2022. "The Aspiration payment is optional; if contractors do not want to claim it, it will not impact on the contractor's ability to claim a PQS payment during the declaration period. There is also no requirement to have claimed for a previous PQS to claim an Aspiration payment for PQS 2022/23," said PSNC.
pharmacybiz

9,000 Pharmacy Contractors Benefited From Advance Payment - 0 views

  •  
    Nearly 9,000 pharmacy contractors benefitted from earlier advance payment in January, Pharmaceutical Services Negotiating Committee (PSNC) said in an update. Contractors who declared their December FP34C submission figures (for the dispensed prescriptions) through the Manage Your Service (MYS) portal by January 6, would have received earlier advance payments on January 12. Meanwhile, all contractors who made submissions after January 6 or used the FP34C paper document, will receive payments as per the normal payment schedule i.e. on February 1, 2022. PSNC encouraged contractors to submit their monthly declaration through the MYS portal by the 5th of the month to avail early payments.
pharmacybiz

Covid Inquiry Questions DHSC on NPA Evidence: Community Pharmacies' Pandemic Struggles - 0 views

  •  
    At the Covid Inquiry on Tuesday, Sir Chris Wormald, permanent secretary at the Department of Health and Social Care (DHSC), was questioned about the initial exclusion of community pharmacies in the government's emergency pandemic life assurance scheme. Earlier this month, the National Pharmacy Association (NPA) submitted evidence to the inquiry highlighting the delay in including community pharmacies in the scheme - which offered £60,000 lump sum payments to NHS and care home staff who died from Covid. The inquiry heard that the scheme was launched on April 27, 2020, initially covering NHS and care home staff. However, then Health Secretary Matt Hancock only confirmed the inclusion of community pharmacy staff in a Tweet three days later, on April 30. NPA Chair Nick Kaye told the inquiry that it was "demoralising and demotivating" to community pharmacy staff who worked throughout the pandemic. Jacqueline Carey KC, Counsel to the Covid Inquiry, put the charge to Sir Wormald as he gave evidence about the department's response to the pandemic.
pharmacybiz

Revised PhAS: Contractors Receive First New Monthly Payment - 0 views

  •  
    Community pharmacy contractors eligible under the revised Pharmacy Access Scheme (PhAS) will receive their first of the new monthly payments with the January reconciliation payment due on April 1, 2022. Details of the revised version of the PhAS that commenced from January 1, was published in August 2021, with contractors receiving letters from the NHS Business Services Authority (NHSBSA) indicating their eligibility in the Autumn, PSNC said in an update. Payments under the scheme are dependent on registration on NHSBSA's Manage Your Service (MYS) portal to provide the Community Pharmacist Consultation Service(CPCS). Meanwhile, the review application window is now open for contractors, which would enable the NHS England and NHS Improvement (NHSE&I) to correct inaccuracies related to a pharmacy's distance criteria/calculation.
pharmacybiz

BGMA:Judicial review on being excluded from VPAS negotiation - 0 views

  •  
    The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI). Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS). "We are deeply concerned by this decision. It has left us no choice but to take legal action." "While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028." "The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS. The association had raised its full participation in the negotiations with the Government last November.
pharmacybiz

HRT prepayment scheme:37k certificates purchased - 0 views

  •  
    The new Hormone Replacement Therapy (HRT) prescription pre-payment certificate (PPC) has witnessed more than 37,000 purchases both via online website and in-person in pharmacies since its launch on Saturday (1 April). As of 12pm today (4 April), 37,240 HRT PPCs have been bought online and 501 in-pharmacy, totalling 37,741 certificates. Department of Health and Social Care (DHSC) estimated women have saved over £1.13 million in prescription charges for the year, with the average person saving £30 for a year's supply. The new prescription pre-payment certificate is also predicted to enable around 400,000 women to have cheaper access to menopause support. On the launch of the scheme on Saturday, the huge demand for the much-anticipated certificate meant some patients were unable to access the website on the morning of 1 April. "The NHS Business Service Authority has ensured that the site has been working, allowing thousands of women to continue to successfully purchase a prescription for a year's worth of hormone replacement therapy products which help treat the menopause," said DHSC. Minister for Women's Health Strategy, Maria Caulfield said: "Over 37,700 women have come forward to claim cheaper HRT this weekend alone, showing what happens when we listen to what women want.
pharmacybiz

RCGP Urges NHS To Secure TERS Funding For 2025-26 | Pharmacy Biz - 0 views

  •  
    The Royal College of GPs (RCGP) has warned that patients in deprived areas could face even greater difficulty accessing GP services if funding for the Targeted Enhanced Recruitment Scheme (TERS) is withdrawn. In a letter to NHS England, the College is calling for confirmation that TERS will be extended for 2025/26 and beyond. The scheme, launched in 2016, was designed to attract GP trainees to economically disadvantaged areas, where healthcare provision has historically been inadequate. TERS offers a one-off payment of £20,000 to GP trainees who commit to working in hard-to-recruit-to locations. Over the years, the scheme has successfully recruited over 2,000 GPs. However, with funding for 2025/26 yet to be confirmed, the RCGP is worried that it could be cut from April. The College has expressed concern that discontinuing the scheme could "make it even more difficult to recruit GPs to work in deprived and under-doctored areas where patients are already significantly disadvantaged compared to those in more affluent areas of the country."
pharmacybiz

PSNC asked extra funds to ease pressure on pharmacy business - 0 views

  •  
    The Pharmaceutical Services Negotiating Committee (PSNC) chief executive Janet Morrison has assured contractors that PSNC will continue to raise with the new prime minister all concerning issues that are bothering pharmacy businesses. She felt the "fixed five-year funding settlement that is declining in real terms" was one of the serious factors that is putting a lots of pressure on contractors. PSNC has provided a compelling portfolio of evidence on the impact that pressures are having on the sector, and requested urgent additional funding, she said. Morrison, in her video message shared yesterday (August 24), urged contractors to keep sharing and sending evidences to act on their behalf. She said she is aware "this one of the toughest periods for the businesses" and "I believe that it demands more action from the government." Morrison assured the sector she was aware that contractors were also facing difficulties in "dealing with global medicines market and the challenges on been able to procure medicines within the drug tariff." "I know how hard it is to see the future sustainability of your businesses. I can see you are facing serious workforce pressure, rising cost, shortage of pharmacists, inflation pressure. I know your using facing increase in demand from the patients who has given up on their GPs and turning to you for support and advice."
pharmacybiz

VPAS negotiation:High Court Dismisses BGMA's Claim - 0 views

  •  
    The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."
pharmacybiz

ABPI:Voluntary Scheme for Pricing, Access and Growth - 0 views

  •  
    The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry. It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy. VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for the whole country. The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical research and R&D; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation. The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the highest contributions ever made before the pandemic.
pharmacybiz

Lloyds and PDA agreed pay settlement for store pharmacists - 0 views

  •  
    LloydsPharmacy has offered three per cent increase in base pay backdated to 1 April for its store pharmacists, the union of Pharmacists' Defence Association (PDAU) who represented them has announced. "We are pleased to announce that following a consultation of its members, the PDAU has informed the company that agreement can be reached on the company's latest offer, made in July 2022," said the PDAU. The offer made by the company also includes introduction of an overtime rate of 1.5 times basic pay for each hour worked after contracted hours. This will run for a trial period and be reviewed as part of the next pay round. "All pharmacists will receive an initial £1,000 payment under the proposed LTIP scheme, paid in April 2024. This will be to all in the bargaining unit and will not be dependent on meeting any criteria such as targets," said PDAU.
pharmacybiz

FSB Partnership with Bank of England Against Counterfeit - 0 views

  •  
    The Federation of Small Businesses (FSB) on Thursday (4 December) announced a new strategic partnership with the Bank of England to protect small businesses from the risks associated with accepting counterfeit banknotes. Cash is still the number one customer payment method for 25 per cent of small high street businesses, and cash payments are expected to increase during the festive period, according to FSB. By becoming a Strategic Partner of the Bank of England's Banknote Checking Scheme, the organisation is trying to help its members become aware of the use of counterfeit notes, which has reputational and financial impacts. The FSB is encouraging its members to sign up to the Scheme, which offers training materials to staff so they can identify a counterfeit note at point of sale and know what to do with it, as well as stay up to date with best practice and bank note developments.
pharmacybiz

BGMA Warns significant implications from crippling VPAS rate - 0 views

  •  
    The British Generic Manufacturers Association (BGMA) has warned of the significant implications for future supply as a result of the crippling VPAS rate. The warning comes after the association's judicial review into the Government's decision to bar it from being a full part of the negotiations for the next five-year VPAS period was dismissed. The voluntary scheme for branded medicines pricing and access (VPAS) is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1%, but in 2023 it has soared to 26.5%. All biosimilars and a proportion of the generics market falls into the scheme.
1 - 20 of 23 Next ›
Showing 20 items per page